Építés alatt – nem éles oldal
Belépés
Befejeződött1. fázis

A Study of HS-10518 in Healthy Adult Premenopausal Females in China

A legfontosabb adatok

Ki végzi
West China Second University Hospital
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Fázis
1. fázis
Résztvevők
60 fő vett részt
Kezdés
2025. márc. 11.
Befejezés
2025. szept. 9.
A vizsgálat típusa
Beavatkozással járó, 6 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • HS-10518
  • Placebo
A regiszteradat frissítve
2026. március 25.

Ki vehet részt

Életkor
18 év – 40 év
Nem
Csak nők
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 2 feltétel megnézéseKevesebb

Ki vehet részt

  • Subjects may be enrolled only if they meet all the following criteria:; At the time of signing the informed consent form, the subject must be 18 to 40 years old (inclusive); Confirmed to be a healthy subject through medical assessment, including indicators such as medical history, physical examination, laboratory tests, and 12-lead electrocardiogram (ECG); Regular menstrual cycles for at least 6 months prior to screening, with:; Cycle length: 24 to 32 days; Menstrual period duration: 2 to 7 days;(The first day of menstruation is defined as Day 1 of the menstrual cycle.); Baseline sex hormone levels meet the following requirements: Follicle-Stimulating Hormone (FSH) < 10 IU/L and Estradiol (E2) < 100 pg/mL; in addition, other sex hormone indicators must be assessed by the investigator as normal for the subject to be randomly enrolled; Body weight ≥ 45 kg, and Body Mass Index (BMI) within the range of 18 to 28 kg/m² (inclusive); The subject agrees to use highly effective non-hormonal contraceptive methods from the date of signing the informed consent form until 3 months after the administration of the last dose of the study drug. Highly effective non-hormonal contraceptive methods include:; Continuous abstinence; Surgical sterilization of the subject (performed at least 3 months prior to signing the informed consent form); Surgical sterilization of the subject's sexual partner (performed at least 6 months prior to signing the informed consent form).Other dual non-hormonal contraceptive methods are also acceptable, including:; Condoms with spermicides; Diaphragms with spermicides (used with or without condoms); Cervical caps with spermicides (used with or without condoms); Vaginal sponges with spermicides (used together with condoms); Have a full understanding of the study content, process, and potential adverse reactions, and voluntarily sign the informed consent form

Ki nem vehet részt

  • Subjects will be excluded from the study if they meet any one of the following criteria:; Has a history of abnormal uterine bleeding within 3 months prior to screening; Has never been sexually active; Has consumed foods or beverages rich in caffeine and/or xanthine (e.g., coffee, tea, chocolate, caffeinated carbonated beverages such as cola), tobacco-containing products (e.g., cigarettes), alcohol, or alcohol-containing products within 48 hours prior to drug administration; Has consumed grapefruit, grapefruit juice, bitter orange, bitter orange marmalade, bitter orange juice, or other products containing grapefruit or bitter orange within 7 days prior to the first dose; Has a history of smoking or alcohol abuse within 6 months prior to screening:; Smoking: More than 5 cigarettes per day or equivalent tobacco products; Alcohol abuse: Alcohol consumption of ≥14 units per week (1 unit = 285 mL of beer, 25 mL of spirits with alcohol content ≥40%, or 150 mL of wine); Is suspected of substance abuse involving barbiturates, amphetamines, benzodiazepines, cocaine, opioids, cannabis, methadone, phencyclidine (PCP), tricyclic antidepressants (TCAs), or methamphetamine; Has a positive alcohol breath test or positive urine drug abuse screening result; Is pregnant, lactating, or has a positive serum beta-human chorionic gonadotropin (β-hCG) test at screening; Has a history of malignant tumors (cancer); Has had clinically significant gastrointestinal complaints, a history of gastrointestinal diseases (e.g., Crohn's disease, ulcerative colitis), or a history of surgery that may affect the absorption of the study drug (except for simple appendectomy or hernia repair) within 7 days prior to the first dose; Has a history of migraine, epilepsy, convulsions, depression, or a clinically significant depressive state; Has a history of thyroid or parathyroid dysfunction, or has thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), or free thyroxine (FT4) levels outside the normal reference range-except if the investigator determines that the abnormality does not affect the study; Is within 6 months after childbirth, abortion, or cessation of lactation; Has a history of severe drug hypersensitivity, allergic diseases (e.g., asthma, urticaria, allergic rhinitis), or a history of atopy (allergic to ≥2 allergens)-if the investigator determines that the subject is unsuitable for the study; Has donated blood, lost ≥400 mL of blood, or received a blood transfusion within 3 months prior to screening; or has donated blood or lost ≥200 mL of blood within 1 month prior to screening; Has used any medications (prescription drugs, over-the-counter (OTC) drugs, traditional Chinese medicines, dietary supplements including vitamins, etc.) or short-term topical medications within 4 weeks prior to the first dose (or at least 5 times the respective elimination half-life, whichever is longer)-except if the investigator determines that the use does not affect the study; Has positive results for hepatitis B surface antigen (HBsAg), hepatitis C antibody (anti-HCV), human immunodeficiency virus antibody (anti-HIV), or syphilis serological test (TRUST)/treponema pallidum antibody (TP-Ab) at screening-except for subjects judged by the investigator to have a history of syphilis but have been cured; Has alanine transaminase (ALT) or aspartate transaminase (AST) levels exceeding the upper limit of normal (ULN) at screening; Has serum creatinine > 1.5 × ULN, or an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m² (calculated using the Modification of Diet in Renal Disease (MDRD) formula) at screening; Has abnormal and clinically significant electrocardiogram (ECG) findings at screening (e.g., absolute value of QTcF [QT interval corrected by Fridericia's formula: QT/RR⁰·³³] > 470 milliseconds [ms]); Has diseases related to the ovaries, breasts, uterus, hypothalamus, or pituitary gland-if the investigator determines that the subject is unsuitable for the study; Has sonographic evidence of physiological abnormalities in the uterus and bilateral ovaries-if the investigator determines that the subject is unsuitable for the study; Has abnormal and clinically significant results from a cervical ThinPrep cytology test (TCT) during screening or within the past 12 months; for subjects with TCT results of "atypical squamous cells of undetermined significance (ASC-US)", enrollment is permitted only if high-risk human papillomavirus (HPV) testing is negative; Has recently used prohibited medications:; Used short-acting preparations containing sex hormones or affecting sex hormone levels (oral, transdermal, intravaginal, etc.) within 3 months prior to the first dose; Used long-acting preparations containing sex hormones or affecting sex hormone levels (any long-acting injections or implants) within 6 months prior to the first dose; Plans to become pregnant during the study or within 3 months after the study ends; Participated in other clinical drug trials within 3 months prior to screening; Has other conditions or reasons deemed by the investigator to make the subject unsuitable for participation in the clinical study

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HS-10518 in healthy adult premenopausal females in China

A vizsgálat 6 csoportja

  • HS-10518 Dose 1A vizsgált kezelés

    Dose level 1 of HS-10518, 10 mg Q12h, orally, 14 days

    Kezelés: HS-10518

  • HS-10518 Dose 2A vizsgált kezelés

    Dose leve2 of HS-10518, 20 mg QD, orally, 14 days

    Kezelés: HS-10518

  • HS-10518 Dose 3A vizsgált kezelés

    Dose leve3 of HS-10518, 20 mg Q12h, orally, 14 days

    Kezelés: HS-10518

  • HS-10518 Dose 4A vizsgált kezelés

    Dose leve4 of HS-10518, 40 mg QD, orally, 14 days

    Kezelés: HS-10518

  • HS-10518 Dose 5A vizsgált kezelés

    Dose leve5 of HS-10518, 80 mg QD, orally, 14 days

    Kezelés: HS-10518

  • PlaceboPlacebo, összehasonlításként

    placebo, BID, orally, 14 days

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HS-10518 in Healthy Adult Premenopausal Females in China
A regiszteradat frissítve
2026. március 25.